Acute graft-versus-host disease.
Journal
Nature reviews. Disease primers
ISSN: 2056-676X
Titre abrégé: Nat Rev Dis Primers
Pays: England
ID NLM: 101672103
Informations de publication
Date de publication:
08 Jun 2023
08 Jun 2023
Historique:
accepted:
02
05
2023
medline:
12
6
2023
pubmed:
9
6
2023
entrez:
8
6
2023
Statut:
epublish
Résumé
Acute graft-versus-host disease (GVHD) is a common immune complication that can occur after allogeneic haematopoietic cell transplantation (alloHCT). Acute GVHD is a major health problem in these patients, and is associated with high morbidity and mortality. Acute GVHD is caused by the recognition and the destruction of the recipient tissues and organs by the donor immune effector cells. This condition usually occurs within the first 3 months after alloHCT, but later onset is possible. Targeted organs include the skin, the lower and upper gastrointestinal tract and the liver. Diagnosis is mainly based on clinical examination, and complementary examinations are performed to exclude differential diagnoses. Preventive treatment for acute GVHD is administered to all patients who receive alloHCT, although it is not always effective. Steroids are used for first-line treatment, and the Janus kinase 2 (JAK2) inhibitor ruxolitinib is second-line treatment. No validated treatments are available for acute GVHD that is refractory to steroids and ruxolitinib, and therefore it remains an unmet medical need.
Identifiants
pubmed: 37291149
doi: 10.1038/s41572-023-00438-1
pii: 10.1038/s41572-023-00438-1
doi:
Substances chimiques
ruxolitinib
82S8X8XX8H
Pyrazoles
0
Nitriles
0
Steroids
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
27Informations de copyright
© 2023. Springer Nature Limited.
Références
Van Bekkum, D., Vos, O. & Weyzen, W. W. The pathogenesis of the secondary disease after foreign bone marrow transplantation in X-irradiated mice. J. Natl Cancer Inst. 23, 75–89 (1959).
pubmed: 13798388
Billingham, R. E. The biology of graft-versus-host reactions. Harvey Lect. 62, 21–78 (1966).
pubmed: 4875305
Passweg, J. R. et al. Hematopoietic cell transplantation and cellular therapy survey of the EBMT: monitoring of activities and trends over 30 years. Bone Marrow Transplant. https://doi.org/10.1038/s41409-021-01227-8 (2021).
doi: 10.1038/s41409-021-01227-8
pubmed: 34775480
pmcid: 8821015
Passweg, J. R. et al. Impact of the SARS-CoV-2 pandemic on hematopoietic cell transplantation and cellular therapies in Europe 2020: a report from the EBMT activity survey. Bone Marrow Transplant. 57, 742–752 (2022).
pubmed: 35194156
pmcid: 8862400
doi: 10.1038/s41409-022-01604-x
Niederwieser, D. et al. One and a half million hematopoietic stem cell transplants: continuous and differential improvement in worldwide access with the use of non-identical family donors. Haematologica 107, 1045–1053 (2022).
pubmed: 34382386
doi: 10.3324/haematol.2021.279189
Holtan, S. G. et al. Disease progression, hospital readmissions, and clinical outcomes for patients with steroid-refractory acute graft-versus-host disease: a multicenter, retrospective study. Bone Marrow Transplant. 57, 1399–1404 (2022).
pubmed: 35739326
pmcid: 9439948
doi: 10.1038/s41409-022-01736-0
Filipovich, A. H. et al. National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. Diagnosis and Staging Working Group report. Biol. Blood Marrow Transplant. 11, 945–956 (2005). This article reports the refined classification by the NIH that established that acute and chronic GVHD should be distinguished based on GVHD features and not time of onset.
pubmed: 16338616
doi: 10.1016/j.bbmt.2005.09.004
Jagasia, M. H. et al. National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group report. Biol. Blood Marrow Transplant. 21, 389–401.e1 (2015).
pubmed: 25529383
doi: 10.1016/j.bbmt.2014.12.001
Harris, A. C. et al. International, multicenter standardization of acute graft-versus-host disease clinical data collection: a report from the Mount Sinai Acute GVHD International Consortium. Biol. Blood Marrow Transplant. 22, 4–10 (2016). This article refines acute GVHD diagnosis criteria to allow better standardization of data collection.
pubmed: 26386318
doi: 10.1016/j.bbmt.2015.09.001
Cahn, J. Y. et al. Prospective evaluation of 2 acute graft-versus-host (GVHD) grading systems: a joint Société Française de Greffe de Moëlle et Thérapie Cellulaire (SFGM-TC), Dana Farber Cancer Institute (DFCI), and International Bone Marrow Transplant Registry (IBMTR) prospective study. Blood 106, 1495–1500 (2005).
pubmed: 15878974
pmcid: 1895210
doi: 10.1182/blood-2004-11-4557
Schoemans, H. M. et al. The eGVHD app has the potential to improve the accuracy of graft-versus-host disease assessment: a multicenter randomized controlled trial. Haematologica 103, 1698–1707 (2018).
pubmed: 29903762
pmcid: 6165809
doi: 10.3324/haematol.2018.190777
Schoemans, H. M. et al. Accuracy and usability of the eGVHD app in assessing the severity of graft-versus-host disease at the 2017 EBMT annual congress. Bone Marrow Transplant. 53, 490–494 (2018).
pubmed: 29330389
doi: 10.1038/s41409-017-0017-0
Thomas, E. D. et al. One hundred patients with acute leukemia treated by chemotherapy, total body irradiation, and allogeneic marrow transplantation. Blood 49, 511–533 (1977).
pubmed: 14751
doi: 10.1182/blood.V49.4.511.511
Reshef, R. et al. Acute GVHD diagnosis and adjudication in a multicenter trial: a report from the BMT CTN 1202 biorepository study. J. Clin. Oncol. 39, 1878–1887 (2021).
pubmed: 33507810
pmcid: 8260916
doi: 10.1200/JCO.20.00619
Greinix, H. T. et al. Improved outcome of patients with graft-versus-host disease after allogeneic hematopoietic cell transplantation for hematologic malignancies over time: an EBMT mega-file study. Haematologica 107, 1054–1063 (2022). This paper is the largest and most recent analysis of acute GVHD incidence, risk factors and outcomes.
pubmed: 34162176
doi: 10.3324/haematol.2020.265769
Mielcarek, M. et al. Effects of race on survival after stem cell transplantation. Biol. Blood Marrow Transplant. 11, 231–239 (2005).
pubmed: 15744242
doi: 10.1016/j.bbmt.2004.12.327
Sigmund, A. M. et al. Impact of race and geographic area of residence on outcomes after allogeneic stem cell transplant. Front. Oncol. https://doi.org/10.3389/fonc.2022.801879 (2022).
doi: 10.3389/fonc.2022.801879
pubmed: 35280722
pmcid: 8913574
Hamilton, B. K. et al. Racial differences in allogeneic hematopoietic cell transplantation outcomes among African Americans and whites. Bone Marrow Transplant. 50, 834–839 (2015).
pubmed: 25798671
doi: 10.1038/bmt.2015.44
Morishima, Y. et al. Significance of ethnicity in the risk of acute graft-versus-host disease and leukemia relapse after unrelated donor hematopoietic stem cell transplantation. Biol. Blood Marrow Transplant. 19, 1197–1203 (2013).
pubmed: 23747601
pmcid: 3972059
doi: 10.1016/j.bbmt.2013.05.020
Kanda, J. et al. Graft-versus-host disease after HLA-matched sibling bone marrow or peripheral blood stem cell transplantation: comparison of North American Caucasian and Japanese populations. Biol. Blood Marrow Transplant. 22, 744–751 (2016).
pubmed: 26762681
pmcid: 4801761
doi: 10.1016/j.bbmt.2015.12.027
Khoury, H. J. et al. Improved survival after acute graft-versus-host disease diagnosis in the modern era. Haematologica 102, 958–966 (2017).
pubmed: 28302712
pmcid: 5477615
doi: 10.3324/haematol.2016.156356
El-Jawahri, A. et al. Improved treatment-related mortality and overall survival of patients with grade IV acute GVHD in the modern years. Biol. Blood Marrow Transplant. 22, 910–918 (2016).
pubmed: 26748160
doi: 10.1016/j.bbmt.2015.12.024
Flowers, M. E. et al. Comparative analysis of risk factors for acute graft-versus-host disease and for chronic graft-versus-host disease according to National Institutes of Health consensus criteria. Blood 117, 3214–3219 (2011).
pubmed: 21263156
pmcid: 3062319
doi: 10.1182/blood-2010-08-302109
Lee, S. J. et al. High-resolution donor-recipient HLA matching contributes to the success of unrelated donor marrow transplantation. Blood 110, 4576–4583 (2007).
pubmed: 17785583
doi: 10.1182/blood-2007-06-097386
Hahn, T. et al. Risk factors for acute graft-versus-host disease after human leukocyte antigen-identical sibling transplants for adults with leukemia. J. Clin. Oncol. 26, 5728–5734 (2008).
pubmed: 18981462
pmcid: 2645611
doi: 10.1200/JCO.2008.17.6545
Gale, R. P. et al. Risk factors for acute graft-versus-host disease. Br. J. Haematol. 67, 397–406 (1987).
pubmed: 3322360
doi: 10.1111/j.1365-2141.1987.tb06160.x
Kollman, C. et al. Donor characteristics as risk factors in recipients after transplantation of bone marrow from unrelated donors: the effect of donor age. Blood 98, 2043–2051 (2001).
pubmed: 11567988
doi: 10.1182/blood.V98.7.2043
Bacigalupo, A. Post-transplant cyclophosphamide: overcoming the HLA barrier to hematopoietic stem cell transplants. Haematologica 107, 1230–1231 (2022).
pubmed: 35642483
pmcid: 9152978
doi: 10.3324/haematol.2022.281256
Im, A. et al. Risk factors for graft-versus-host disease in haploidentical hematopoietic cell transplantation using post-transplant cyclophosphamide. Biol. Blood Marrow Transplant. 26, 1459–1468 (2020).
pubmed: 32434056
pmcid: 7391266
doi: 10.1016/j.bbmt.2020.05.001
Hansen, J. A., Chien, J. W., Warren, E. H., Zhao, L. P. & Martin, P. J. Defining genetic risk for graft-versus-host disease and mortality following allogeneic hematopoietic stem cell transplantation. Curr. Opin. Hematol. 17, 483–492 (2010).
pubmed: 20827186
pmcid: 3177530
doi: 10.1097/MOH.0b013e32833eb770
Antin, J. H. & Ferrara, J. L. Cytokine dysregulation and acute graft-versus-host disease. Blood 80, 2964–2968 (1992).
pubmed: 1467511
doi: 10.1182/blood.V80.12.2964.2964
Holler, E. et al. Increased serum levels of tumor necrosis factor alpha precede major complications of bone marrow transplantation. Blood 75, 1011–1016 (1990).
pubmed: 2405918
doi: 10.1182/blood.V75.4.1011.1011
Storb, R. et al. Allogeneic hematopoietic cell transplantation following minimal intensity conditioning: predicting acute graft-versus-host disease and graft-versus-tumor effects. Biol. Blood Marrow Transplant. 19, 792–798 (2013).
pubmed: 23416851
pmcid: 3629007
doi: 10.1016/j.bbmt.2013.02.006
Cooke, K. R., Olkiewicz, K., Erickson, N. & Ferrara, J. L. The role of endotoxin and the innate immune response in the pathophysiology of acute graft versus host disease. J. Endotoxin Res. 8, 441–448 (2002).
pubmed: 12697087
doi: 10.1177/09680519020080061301
Holler, E. et al. Both donor and recipient NOD2/CARD15 mutations associate with transplant-related mortality and GvHD following allogeneic stem cell transplantation. Blood 104, 889–894 (2004).
pubmed: 15090455
doi: 10.1182/blood-2003-10-3543
Holler, E. et al. Prognostic significance of NOD2/CARD15 variants in HLA-identical sibling hematopoietic stem cell transplantation: effect on long-term outcome is confirmed in 2 independent cohorts and may be modulated by the type of gastrointestinal decontamination. Blood 107, 4189–4193 (2006).
pubmed: 16424393
doi: 10.1182/blood-2005-09-3741
Markus, M. H. et al. MyD88/TLR9 mediated immunopathology and gut microbiota dynamics in a novel murine model of intestinal graft-versus-host disease. Gut 59, 1079–1087 (2010).
doi: 10.1136/gut.2009.197434
Fischer, J. C. et al. RIG-I/MAVS and STING signaling promote gut integrity during irradiation- and immune-mediated tissue injury. Sci. Transl Med. https://doi.org/10.1126/scitranslmed.aag2513 (2017).
doi: 10.1126/scitranslmed.aag2513
pubmed: 28931655
pmcid: 5747528
Bader, C. S. et al. STING differentially regulates experimental GVHD mediated by CD8 versus CD4 T cell subsets. Sci. Transl Med. https://doi.org/10.1126/scitranslmed.aay5006 (2020).
doi: 10.1126/scitranslmed.aay5006
pubmed: 32669421
pmcid: 7392054
Toubai, T., Mathewson, N. D., Magenau, J. & Reddy, P. Danger signals and graft-versus-host disease: current understanding and future perspectives. Front. Immunol. 7, 539 (2016).
pubmed: 27965667
pmcid: 5126092
doi: 10.3389/fimmu.2016.00539
Wilhelm, K. et al. Graft-versus-host disease is enhanced by extracellular ATP activating P2X7R. Nat. Med. 16, 1434–1438 (2010).
pubmed: 21102458
doi: 10.1038/nm.2242
Vander Lugt, M. T. et al. ST2 as a marker for risk of therapy-resistant graft-versus-host disease and death. N. Engl. J. Med. 369, 529–539 (2013).
doi: 10.1056/NEJMoa1213299
van Bekkum, D. W., Roodenburg, J., Heidt, P. J. & van der Waaij, D. Mitigation of secondary disease of allogeneic mouse radiation chimeras by modification of the intestinal microflora. J. Natl Cancer Inst. 52, 401–404 (1974).
pubmed: 4150164
doi: 10.1093/jnci/52.2.401
Storb, R. et al. Graft-versus-host disease and survival in patients with aplastic anemia treated by marrow grafts from HLA-identical siblings. Beneficial effect of a protective environment. N. Engl. J. Med. 308, 302–307 (1983).
pubmed: 6337323
doi: 10.1056/NEJM198302103080602
Hulsdunker, J. et al. Neutrophils provide cellular communication between ileum and mesenteric lymph nodes at graft-versus-host disease onset. Blood 131, 1858–1869 (2018).
pubmed: 29463561
pmcid: 5909763
doi: 10.1182/blood-2017-10-812891
Vossen, J. M. et al. Complete suppression of the gut microbiome prevents acute graft-versus-host disease following allogeneic bone marrow transplantation. PLoS ONE 9, e105706 (2014).
pubmed: 25180821
pmcid: 4152127
doi: 10.1371/journal.pone.0105706
Peled, J. U. et al. Microbiota as predictor of mortality in allogeneic hematopoietic-cell transplantation. N. Engl. J. Med. 382, 822–834 (2020).
pubmed: 32101664
pmcid: 7534690
doi: 10.1056/NEJMoa1900623
Stein-Thoeringer, C. K. et al. Lactose drives Enterococcus expansion to promote graft-versus-host disease. Science 366, 1143–1149 (2019).
pubmed: 31780560
pmcid: 7003985
doi: 10.1126/science.aax3760
Jenq, R. R. et al. Intestinal Blautia is associated with reduced death from graft-versus-host disease. Biol. Blood Marrow Transplant. 21, 1373–1383 (2015).
pubmed: 25977230
pmcid: 4516127
doi: 10.1016/j.bbmt.2015.04.016
Riwes, M. & Reddy, P. Short chain fatty acids: postbiotics/metabolites and graft versus host disease colitis. Semin. Hematol. 57, 1–6 (2020).
pubmed: 32690138
pmcid: 9387163
doi: 10.1053/j.seminhematol.2020.06.001
Ghimire, S. et al. Low intestinal IL22 associates with increased transplant-related mortality after allogeneic stem cell transplantation. Front. Immunol. 13, 857400 (2022).
pubmed: 35572572
pmcid: 9103485
doi: 10.3389/fimmu.2022.857400
Arpaia, N. et al. Metabolites produced by commensal bacteria promote peripheral regulatory T-cell generation. Nature 504, 451–455 (2013).
pubmed: 24226773
pmcid: 3869884
doi: 10.1038/nature12726
Fujiwara, H. et al. Microbial metabolite sensor GPR43 controls severity of experimental GVHD. Nat. Commun. 9, 3674 (2018).
pubmed: 30201970
pmcid: 6131147
doi: 10.1038/s41467-018-06048-w
Kambayashi, T. & Laufer, T. M. Atypical MHC class II-expressing antigen-presenting cells: can anything replace a dendritic cell? Nat. Rev. Immunol. 14, 719–730 (2014).
pubmed: 25324123
doi: 10.1038/nri3754
Shlomchik, W. D. et al. Prevention of graft versus host disease by inactivation of host antigen-presenting cells. Science 285, 412–415 (1999).
pubmed: 10411505
doi: 10.1126/science.285.5426.412
Duffner, U. A. et al. Host dendritic cells alone are sufficient to initiate acute graft-versus-host disease. J. Immunol. 172, 7393–7398 (2004).
pubmed: 15187116
doi: 10.4049/jimmunol.172.12.7393
Matte, C. C. et al. Donor APCs are required for maximal GVHD but not for GVL. Nat. Med. 10, 987–992 (2004).
pubmed: 15286785
doi: 10.1038/nm1089
Koyama, M. & Hill, G. R. Alloantigen presentation and graft-versus-host disease: fuel for the fire. Blood 127, 2963–2970 (2016).
pubmed: 27030390
doi: 10.1182/blood-2016-02-697250
Koyama, M. et al. Recipient nonhematopoietic antigen-presenting cells are sufficient to induce lethal acute graft-versus-host disease. Nat. Med. 18, 135–142 (2011).
pubmed: 22127134
doi: 10.1038/nm.2597
Ruggeri, A. et al. Integrating biological HLA-DPB1 mismatch models to predict survival after unrelated hematopoietic cell transplantation. Haematologica 108, 645–652 (2023).
pubmed: 35546480
doi: 10.3324/haematol.2021.280055
Neefjes, J., Jongsma, M. L., Paul, P. & Bakke, O. Towards a systems understanding of MHC class I and MHC class II antigen presentation. Nat. Rev. Immunol. 11, 823–836 (2011).
pubmed: 22076556
doi: 10.1038/nri3084
Goulmy, E. et al. Mismatches of minor histocompatibility antigens between HLA-identical donors and recipients and the development of graft-versus-host disease after bone marrow transplantation. N. Engl. J. Med. 334, 281–285 (1996).
pubmed: 8532022
doi: 10.1056/NEJM199602013340501
Meyer, E. H. et al. Transplantation of donor grafts with defined ratio of conventional and regulatory T cells in HLA-matched recipients. JCI Insight https://doi.org/10.1172/jci.insight.127244 (2019).
doi: 10.1172/jci.insight.127244
pubmed: 31092732
pmcid: 6542607
Edinger, M. et al. CD4
pubmed: 12925844
doi: 10.1038/nm915
Yang, J. et al. Rorc restrains the potency of ST2
doi: 10.1172/jci.insight.122014
pubmed: 31852845
pmcid: 6975273
Delacher, M. et al. Single-cell chromatin accessibility landscape identifies tissue repair program in human regulatory T cells. Immunity 54, 702–720.e17 (2021).
pubmed: 33789089
pmcid: 8050210
doi: 10.1016/j.immuni.2021.03.007
Robb, R. J. et al. Identification and expansion of highly suppressive CD8
pubmed: 22538855
doi: 10.1182/blood-2011-12-396119
Hu, Y. et al. Regulatory B cells promote graft-versus-host disease prevention and maintain graft-versus-leukemia activity following allogeneic bone marrow transplantation. Oncoimmunology 6, e1284721 (2017).
pubmed: 28405514
pmcid: 5384367
doi: 10.1080/2162402X.2017.1284721
Le Blanc, K., Jitschin, R. & Mougiakakos, D. Myeloid-derived suppressor cells in allogeneic hematopoietic stem cell transplantation: a double-edged sword? Oncoimmunology 2, e25009 (2013).
pubmed: 24073377
pmcid: 3782166
doi: 10.4161/onci.25009
Demosthenous, C. et al. The role of myeloid-derived suppressor cells (MDSCs) in graft-versus-host disease (GVHD). J. Clin. Med. 10, 2050 (2021).
pubmed: 34064671
pmcid: 8150814
doi: 10.3390/jcm10102050
Riquelme, P. et al. TIGIT
pubmed: 30030423
pmcid: 6054648
doi: 10.1038/s41467-018-05167-8
Quatrini, L. et al. Helper innate lymphoid cells in allogenic hematopoietic stem cell transplantation and graft versus host disease. Front. Immunol. 11, 582098 (2020).
pubmed: 33101308
pmcid: 7554507
doi: 10.3389/fimmu.2020.582098
Luft, T. et al. Serum cytokeratin-18 fragments as quantitative markers of epithelial apoptosis in liver and intestinal graft-versus-host disease. Blood 110, 4535–4542 (2007).
pubmed: 17702900
doi: 10.1182/blood-2006-10-049817
Glucksberg, H. et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors. Transplantation 18, 295–304 (1974).
pubmed: 4153799
doi: 10.1097/00007890-197410000-00001
Fu, Y. Y. et al. T cell recruitment to the intestinal stem cell compartment drives immune-mediated intestinal damage after allogeneic transplantation. Immunity 51, 90–103.e3 (2019).
pubmed: 31278057
pmcid: 7239328
doi: 10.1016/j.immuni.2019.06.003
Matsuzawa-Ishimoto, Y. et al. Autophagy protein ATG16L1 prevents necroptosis in the intestinal epithelium. J. Exp. Med. 214, 3687–3705 (2017).
pubmed: 29089374
pmcid: 5716041
doi: 10.1084/jem.20170558
Hill, G. R., Krenger, W. & Ferrara, J. L. The role of cytokines in acute graft-versus-host disease. Cytokines Cell. Mol. Ther. 3, 257–266 (1997).
pubmed: 9740354
Spoerl, S. et al. Activity of therapeutic JAK 1/2 blockade in graft-versus-host disease. Blood 123, 3832–3842 (2014).
pubmed: 24711661
doi: 10.1182/blood-2013-12-543736
Dietrich, S. et al. Endothelial vulnerability and endothelial damage are associated with risk of graft-versus-host disease and response to steroid treatment. Biol. Blood Marrow Transplant. 19, 22–27 (2013).
pubmed: 23041600
doi: 10.1016/j.bbmt.2012.09.018
Biedermann, B. C. et al. Endothelial injury mediated by cytotoxic T lymphocytes and loss of microvessels in chronic graft versus host disease. Lancet 359, 2078–2083 (2002).
pubmed: 12086762
doi: 10.1016/S0140-6736(02)08907-9
Mathew, N. R. et al. Graft-versus-host disease of the CNS is mediated by TNF upregulation in microglia. J. Clin. Invest. 130, 1315–1329 (2020).
pubmed: 31846439
pmcid: 7269577
doi: 10.1172/JCI130272
Hildebrandt, G. C. et al. Donor-derived TNF-α regulates pulmonary chemokine expression and the development of idiopathic pneumonia syndrome after allogeneic bone marrow transplantation. Blood 104, 586–593 (2004).
pubmed: 15069018
doi: 10.1182/blood-2003-12-4259
Wu, S. R. & Reddy, P. Tissue tolerance: a distinct concept to control acute GVHD severity. Blood 129, 1747–1752 (2017).
pubmed: 28153825
pmcid: 5374290
doi: 10.1182/blood-2016-09-740431
Fujiwara, H. et al. Mitochondrial complex II in intestinal epithelial cells regulates T cell-mediated immunopathology. Nat. Immunol. 22, 1440–1451 (2021).
pubmed: 34686860
pmcid: 9351914
doi: 10.1038/s41590-021-01048-3
Mohamed, F. A. et al. Recent metabolic advances for preventing and treating acute and chronic graft versus host disease. Front. Immunol. 12, 757836 (2021).
pubmed: 34712243
pmcid: 8546182
doi: 10.3389/fimmu.2021.757836
Holtan, S. G. et al. Disease progression, treatments, hospitalization, and clinical outcomes in acute GVHD: a multicenter chart review. Bone Marrow Transplant. 57, 1581–1585 (2022).
pubmed: 35908108
pmcid: 9576589
doi: 10.1038/s41409-022-01764-w
Champlin, R. E. et al. Blood stem cells compared with bone marrow as a source of hematopoietic cells for allogeneic transplantation. IBMTR Histocompatibility and Stem Cell Sources Working Committee and the European Group for Blood and Marrow Transplantation (EBMT). Blood 95, 3702–3709 (2000).
pubmed: 10845900
Lerner, K. G. et al. Histopathology of graft-vs.-host reaction (GvHR) in human recipients of marrow from HL-A-matched sibling donors. Transplant. Proc. 6, 367–371 (1974).
pubmed: 4155153
Weisdorf, D. J. et al. Acute upper gastrointestinal graft-versus-host disease: clinical significance and response to immunosuppressive therapy. Blood 76, 624–629 (1990).
pubmed: 2378989
doi: 10.1182/blood.V76.3.624.624
Cox, G. J. et al. Etiology and outcome of diarrhea after marrow transplantation: a prospective study. Gastroenterology 107, 1398–1407 (1994).
pubmed: 7926504
doi: 10.1016/0016-5085(94)90542-8
Kalantari, B. N. et al. CT features with pathologic correlation of acute gastrointestinal graft-versus-host disease after bone marrow transplantation in adults. AJR Am. J. Roentgenol. 181, 1621–1625 (2003).
pubmed: 14627585
doi: 10.2214/ajr.181.6.1811621
Thompson, B., Salzman, D., Steinhauer, J., Lazenby, A. J. & Wilcox, C. M. Prospective endoscopic evaluation for gastrointestinal graft-versus-host disease: determination of the best diagnostic approach. Bone Marrow Transplant. 38, 371–376 (2006).
pubmed: 16915225
doi: 10.1038/sj.bmt.1705453
Tarantino, G. et al. Gastrointestinal complications after allogeneic hematopoietic stem cell transplant: a multidisciplinary approach with early endoscopic evaluation. Clin. Hematol. Int. 3, 161–168 (2021).
pubmed: 34938988
pmcid: 8690703
doi: 10.2991/chi.k.210826.001
Shabbir, E., Farooq, U., Yanes, B. & Magalhaes-Silverman, M. Repeat endoscopy affects patient management in gastrointestinal graft-versus-host disease. Clin. Hematol. Int. 2, 69–73 (2020).
pubmed: 34595445
pmcid: 8432351
doi: 10.2991/chi.d.200220.001
Sale, G. E., Shulman, H. M., McDonald, G. B. & Thomas, E. D. Gastrointestinal graft-versus-host disease in man. A clinicopathologic study of the rectal biopsy. Am. J. Surg. Pathol. 3, 291–299 (1979).
pubmed: 44107
doi: 10.1097/00000478-197908000-00001
Epstein, R. J., McDonald, G. B., Sale, G. E., Shulman, H. M. & Thomas, E. D. The diagnostic accuracy of the rectal biopsy in acute graft-versus-host disease: a prospective study of thirteen patients. Gastroenterology 78, 764–771 (1980).
pubmed: 6986319
doi: 10.1016/0016-5085(80)90681-2
Schreyer, A. G. et al. Transmural penetration of intravenously applied microbubbles during contrast-enhanced ultrasound as a new diagnostic feature in patients with GVHD of the bowel. Bone Marrow Transplant. 46, 1006–1011 (2011).
pubmed: 20935683
doi: 10.1038/bmt.2010.232
Schreyer, A. G. et al. Contrast-enhanced ultrasound for differential diagnosis of suspected GvHD in patients after allogeneic transplantation. Clin. Hemorheol. Microcirc. 49, 129–136 (2011).
pubmed: 22214684
doi: 10.3233/CH-2011-1463
Benedetti, E. et al. Prospective qualitative and quantitative non-invasive evaluation of intestinal acute GVHD by contrast-enhanced ultrasound sonography. Bone Marrow Transplant. 48, 1421–1428 (2013).
pubmed: 23665821
doi: 10.1038/bmt.2013.65
Stelljes, M. et al. Clinical molecular imaging in intestinal graft-versus-host disease: mapping of disease activity, prediction, and monitoring of treatment efficiency by positron emission tomography. Blood 111, 2909–2918 (2008).
pubmed: 18057227
doi: 10.1182/blood-2007-10-119164
Gooley, T. A. et al. Reduced mortality after allogeneic hematopoietic-cell transplantation. N. Engl. J. Med. 363, 2091–2101 (2010).
pubmed: 21105791
pmcid: 3017343
doi: 10.1056/NEJMoa1004383
Snover, D. C., Weisdorf, S. A., Ramsay, N. K., McGlave, P. & Kersey, J. H. Hepatic graft versus host disease: a study of the predictive value of liver biopsy in diagnosis. Hepatology 4, 123–130 (1984).
pubmed: 6363248
doi: 10.1002/hep.1840040122
Cooke, K. R. & Yanik, G. Acute lung injury after allogeneic stem cell transplantation: is the lung a target of acute graft-versus-host disease. Bone Marrow Transplant. 34, 753–765 (2004).
pubmed: 15300233
doi: 10.1038/sj.bmt.1704629
Krenger, W., Blazar, B. R. & Holländer, G. A. Thymic T-cell development in allogeneic stem cell transplantation. Blood 117, 6768–6776 (2011).
pubmed: 21427289
pmcid: 3128475
doi: 10.1182/blood-2011-02-334623
Ding, L. et al. Tumor necrosis factor α in aGVHD patients contributed to the impairment of recipient bone marrow MSC stemness and deficiency of their hematopoiesis-promotion capacity. Stem Cell Res. Ther. 11, 119 (2020).
pubmed: 32183881
pmcid: 7079531
doi: 10.1186/s13287-020-01615-9
Mensen, A. et al. Bone marrow T-cell infiltration during acute GVHD is associated with delayed B-cell recovery and function after HSCT. Blood 124, 963–972 (2014).
pubmed: 24833353
doi: 10.1182/blood-2013-11-539031
Shortt, J., Hutton, E., Faragher, M. & Spencer, A. Central nervous system graft-versus-host disease post allogeneic stem cell transplant. Br. J. Haematol. 132, 245–247 (2006).
pubmed: 16398660
doi: 10.1111/j.1365-2141.2005.05864.x
Przepiorka, D. et al. 1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transplant. 15, 825–828 (1995).
pubmed: 7581076
MacMillan, M. L. et al. Response of 443 patients to steroids as primary therapy for acute graft-versus-host disease: comparison of grading systems. Biol. Blood Marrow Transplant. 8, 387–394 (2002).
pubmed: 12171485
doi: 10.1053/bbmt.2002.v8.pm12171485
Rowlings, P. A. et al. IBMTR severity index for grading acute graft-versus-host disease: retrospective comparison with Glucksberg grade. Br. J. Haematol. 97, 855–864 (1997).
pubmed: 9217189
doi: 10.1046/j.1365-2141.1997.1112925.x
Paczesny, S. et al. A biomarker panel for acute graft-versus-host disease. Blood 113, 273–278 (2009).
pubmed: 18832652
pmcid: 2615645
doi: 10.1182/blood-2008-07-167098
Paczesny, S. et al. Elafin is a biomarker of graft-versus-host disease of the skin. Sci. Transl Med. 2, 13ra12 (2010).
doi: 10.1126/scitranslmed.3000406
Harris, A. C. et al. Plasma biomarkers of lower gastrointestinal and liver acute GVHD. Blood 119, 2960–2963 (2012).
pubmed: 22286196
pmcid: 3327467
doi: 10.1182/blood-2011-10-387357
Ferrara, J. L. et al. Regenerating islet-derived 3-alpha is a biomarker of gastrointestinal graft-versus-host disease. Blood 118, 6702–6708 (2011).
pubmed: 21979939
pmcid: 3242723
doi: 10.1182/blood-2011-08-375006
Hartwell, M. J. et al. An early-biomarker algorithm predicts lethal graft-versus-host disease and survival. JCI insight 2, e89798 (2017).
pubmed: 28194439
pmcid: 5291735
doi: 10.1172/jci.insight.89798
Srinagesh, H. K. et al. The MAGIC algorithm probability is a validated response biomarker of treatment of acute graft-versus-host disease. Blood Advan. 3, 4034–4042 (2019).
doi: 10.1182/bloodadvances.2019000791
Zewde, M. G. et al. Evaluation of elafin as a prognostic biomarker in acute graft-versus-host disease. Transplant. Cell Ther. 27, 988.e1–988.e7 (2021).
pubmed: 34474163
doi: 10.1016/j.jtct.2021.08.021
Storb, R. et al. Methotrexate and cyclosporine compared with cyclosporine alone for prophylaxis of acute graft versus host disease after marrow transplantation for leukemia. N. Engl. J. Med. 314, 729–735 (1986). To our knowledge, the first randomized phase III study that established the combination of methotrexate and a calcineurin as the standard GVHD prophylaxis after alloHCT.
pubmed: 3513012
doi: 10.1056/NEJM198603203141201
Storb, R. et al. Methotrexate and cyclosporine versus cyclosporine alone for prophylaxis of graft-versus-host disease in patients given HLA-identical marrow grafts for leukemia: long-term follow-up of a controlled trial. Blood 73, 1729–1734 (1989).
pubmed: 2653461
doi: 10.1182/blood.V73.6.1729.1729
Ratanatharathorn, V. et al. Phase III study comparing methotrexate and tacrolimus (prograf, FK506) with methotrexate and cyclosporine for graft-versus-host disease prophylaxis after HLA-identical sibling bone marrow transplantation. Blood 92, 2303–2314 (1998).
pubmed: 9746768
Nash, R. A. et al. Phase 3 study comparing methotrexate and tacrolimus with methotrexate and cyclosporine for prophylaxis of acute graft-versus-host disease after marrow transplantation from unrelated donors. Blood 96, 2062–2068 (2000).
pubmed: 10979948
Farouk, S. S. & Rein, J. L. The many faces of calcineurin inhibitor toxicity – what the FK? Adv. Chronic Kidney Dis. 27, 56–66 (2020).
pubmed: 32147003
pmcid: 7080294
doi: 10.1053/j.ackd.2019.08.006
Young, J. A., Pallas, C. R. & Knovich, M. A. Transplant-associated thrombotic microangiopathy: theoretical considerations and a practical approach to an unrefined diagnosis. Bone Marrow Transplant. 56, 1805–1817 (2021).
pubmed: 33875812
pmcid: 8338557
doi: 10.1038/s41409-021-01283-0
Ricklin, D., Hajishengallis, G., Yang, K. & Lambris, J. D. Complement: a key system for immune surveillance and homeostasis. Nat. Immunol. 11, 785–797 (2010).
pubmed: 20720586
pmcid: 2924908
doi: 10.1038/ni.1923
Bolwell, B. et al. A prospective randomized trial comparing cyclosporine and short course methotrexate with cyclosporine and mycophenolate mofetil for GVHD prophylaxis in myeloablative allogeneic bone marrow transplantation. Bone Marrow Transplant. 34, 621–625 (2004).
pubmed: 15300236
doi: 10.1038/sj.bmt.1704647
Kharfan-Dabaja, M. et al. Mycophenolate mofetil versus methotrexate for prevention of graft-versus-host disease in people receiving allogeneic hematopoietic stem cell transplantation. Cochrane Database Syst. Rev. https://doi.org/10.1002/14651858.CD010280.pub2 (2014).
doi: 10.1002/14651858.CD010280.pub2
pubmed: 25061777
Ram, R., Yeshurun, M., Vidal, L., Shpilberg, O. & Gafter-Gvili, A. Mycophenolate mofetil vs. methotrexate for the prevention of graft-versus-host-disease-systematic review and meta-analysis. Leuk. Res 38, 352–360 (2014).
pubmed: 24418750
doi: 10.1016/j.leukres.2013.12.012
Mohty, M. et al. Mycophenolate mofetil and cyclosporine for graft-versus-host disease prophylaxis following reduced intensity conditioning allogeneic stem cell transplantation. Bone Marrow Transplant. 34, 527–530 (2004).
pubmed: 15286687
doi: 10.1038/sj.bmt.1704640
Brunstein, C. G. et al. Umbilical cord blood transplantation after nonmyeloablative conditioning: impact on transplantation outcomes in 110 adults with hematologic disease. Blood 110, 3064–3070 (2007).
pubmed: 17569820
pmcid: 2018678
doi: 10.1182/blood-2007-04-067215
Brissot, E. et al. Prophylaxis with mycophenolate mofetil and CsA can decrease the incidence of severe acute GVHD after antithymocyte globulin-based reduced-intensity preparative regimen and allo-SCT from HLA-matched unrelated donors. Bone Marrow Transplant. 45, 786–788 (2010).
pubmed: 19718059
doi: 10.1038/bmt.2009.218
Penack, O. et al. Prophylaxis and management of graft versus host disease after stem-cell transplantation for haematological malignancies: updated consensus recommendations of the European Society for Blood and Marrow Transplantation. Lancet Haematol. 7, e157–e167 (2020).
pubmed: 32004485
doi: 10.1016/S2352-3026(19)30256-X
Törlén, J. et al. A prospective randomized trial comparing cyclosporine/methotrexate and tacrolimus/sirolimus as graft-versus-host disease prophylaxis after allogeneic hematopoietic stem cell transplantation. Haematologica 101, 1417–1425 (2016).
pubmed: 27662016
pmcid: 5394879
doi: 10.3324/haematol.2016.149294
Sandmaier, B. M. et al. Addition of sirolimus to standard cyclosporine plus mycophenolate mofetil-based graft-versus-host disease prophylaxis for patients after unrelated non-myeloablative haemopoietic stem cell transplantation: a multicentre, randomised, phase 3 trial. Lancet Haematol. 6, e409–e418 (2019).
pubmed: 31248843
pmcid: 6686903
doi: 10.1016/S2352-3026(19)30088-2
Kornblit, B. et al. Sirolimus with CSP and MMF as GVHD prophylaxis for allogeneic transplantation with HLA antigen-mismatched donors. Blood 136, 1499–1506 (2020).
pubmed: 32603426
pmcid: 7515688
doi: 10.1182/blood.2020005338
Watkins, B. et al. Phase II trial of costimulation blockade with abatacept for prevention of acute GVHD. J. Clin. Oncol. 39, 1865–1877 (2021).
pubmed: 33449816
pmcid: 8260909
doi: 10.1200/JCO.20.01086
Urbano-Ispizua, A. et al. Rapid engraftment without significant graft-versus-host disease after allogeneic transplantation of CD34
pubmed: 9166834
doi: 10.1182/blood.V89.11.3967
Wagner, J. E., Thompson, J. S., Carter, S. L. & Kernan, N. A. Effect of graft-versus-host disease prophylaxis on 3-year disease-free survival in recipients of unrelated donor bone marrow (T-cell Depletion Trial): a multi-centre, randomised phase II-III trial. Lancet 366, 733–741 (2005).
pubmed: 16125590
doi: 10.1016/S0140-6736(05)66996-6
Keever-Taylor, C. A. et al. Characteristics of CliniMACS® System CD34-enriched T cell-depleted grafts in a multicenter trial for acute myeloid leukemia – Blood and Marrow Transplant Clinical Trials Network (BMT CTN) protocol 0303. Biol. Blood Marrow Transplant. 18, 690–697 (2012).
pubmed: 21875505
doi: 10.1016/j.bbmt.2011.08.017
Hobbs, G. S. et al. Comparison of outcomes at two institutions of patients with ALL receiving ex vivo T-cell-depleted or unmodified allografts. Bone Marrow Transplant. 50, 493–498 (2015).
pubmed: 25621808
pmcid: 4382422
doi: 10.1038/bmt.2014.302
Barba, P. et al. CD34
pubmed: 29305194
pmcid: 6800017
doi: 10.1016/j.bbmt.2017.12.804
Bertaina, A. et al. HLA-haploidentical stem cell transplantation after removal of αβ
pubmed: 24869942
doi: 10.1182/blood-2014-03-563817
Salzmann-Manrique, E. et al. Joint modeling of immune reconstitution post haploidentical stem cell transplantation in pediatric patients with acute leukemia comparing CD34
pubmed: 30154788
pmcid: 6102342
doi: 10.3389/fimmu.2018.01841
Bleakley, M. et al. Naive T-cell depletion to prevent chronic graft-versus-host disease. J. Clin. Oncol. 40, 1174–1185 (2022).
pubmed: 35007144
pmcid: 8987226
doi: 10.1200/JCO.21.01755
Martelli, M. F. et al. HLA-haploidentical transplantation with regulatory and conventional T-cell adoptive immunotherapy prevents acute leukemia relapse. Blood 124, 638–644 (2014).
pubmed: 24923299
doi: 10.1182/blood-2014-03-564401
Mohty, M. Mechanisms of action of antithymocyte globulin: T-cell depletion and beyond. Leukemia 21, 1387–1394 (2007).
pubmed: 17410187
doi: 10.1038/sj.leu.2404683
Bacigalupo, A. et al. Antithymocyte globulin for graft-versus-host disease prophylaxis in transplants from unrelated donors: 2 randomized studies from Gruppo Italiano Trapianti Midollo Osseo (GITMO). Blood 98, 2942–2947 (2001). To our knowledge, the first randomized study showing that in vivo T cell depletion of antithymocyte globulin added to standard pharmacological GVHD prophylaxis decreases the incidence of acute GVHD.
pubmed: 11698275
doi: 10.1182/blood.V98.10.2942
Finke, J. et al. Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised, open-label, multicentre phase 3 trial. Lancet Oncol. 10, 855–864 (2009).
pubmed: 19695955
doi: 10.1016/S1470-2045(09)70225-6
Kröger, N. et al. Antilymphocyte globulin for prevention of chronic graft-versus-host disease. N. Engl. J. Med. 374, 43–53 (2016).
pubmed: 26735993
doi: 10.1056/NEJMoa1506002
Walker, I. et al. Pretreatment with anti-thymocyte globulin versus no anti-thymocyte globulin in patients with haematological malignancies undergoing haemopoietic cell transplantation from unrelated donors: a randomised, controlled, open-label, phase 3, multicentre trial. Lancet Oncol. 17, 164–173 (2016).
pubmed: 26723083
doi: 10.1016/S1470-2045(15)00462-3
Soiffer, R. J. et al. Prospective, randomized, double-blind, phase III clinical trial of anti-T-lymphocyte globulin to assess impact on chronic graft-versus-host disease-free survival in patients undergoing HLA-matched unrelated myeloablative hematopoietic cell transplantation. J. Clin. Oncol. 35, 4003–4011 (2017).
pubmed: 29040031
pmcid: 8462523
doi: 10.1200/JCO.2017.75.8177
Bonifazi, F. in The EBMT Handbook: Hematopoietic Stem Cell Transplantation and Cellular Therapies (eds Carreras, E., Dufour, C., Mohty, M. & Kröger, N.) 183–187 (Springer, 2019).
Soiffer, R. J. et al. Impact of immune modulation with anti-T-cell antibodies on the outcome of reduced-intensity allogeneic hematopoietic stem cell transplantation for hematologic malignancies. Blood 117, 6963–6970 (2011).
pubmed: 21464372
pmcid: 3128486
doi: 10.1182/blood-2011-01-332007
Luznik, L. et al. HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide. Biol. Blood Marrow Transplant. 14, 641–650 (2008). To our knowledge, the first study reporting the use of post-transplant cyclophosphamide for acute GVHD in patients with a haploidentical donor.
pubmed: 18489989
doi: 10.1016/j.bbmt.2008.03.005
Bashey, A. et al. T-cell-replete HLA-haploidentical hematopoietic transplantation for hematologic malignancies using post-transplantation cyclophosphamide results in outcomes equivalent to those of contemporaneous HLA-matched related and unrelated donor transplantation. J. Clin. Oncol. 31, 1310–1316 (2013).
pubmed: 23423745
doi: 10.1200/JCO.2012.44.3523
Wachsmuth, L. P. et al. Post-transplantation cyclophosphamide prevents graft-versus-host disease by inducing alloreactive T cell dysfunction and suppression. J. Clin. Investig. 129, 2357–2373 (2019).
pubmed: 30913039
doi: 10.1172/JCI124218
Battipaglia, G. et al. Posttransplant cyclophosphamide vs antithymocyte globulin in HLA-mismatched unrelated donor transplantation. Blood 134, 892–899 (2019).
pubmed: 31270102
doi: 10.1182/blood.2019000487
Shaw, B. E. et al. A national marrow donor program sponsored multi-center, phase II trial of HLA- mismatched unrelated donor bone marrow transplantation using post-transplant cyclophosphamide. J. Clin. Oncol. 39, 1971–1982 (2021).
pubmed: 33905264
pmcid: 8260905
doi: 10.1200/JCO.20.03502
Brissot, E. et al. Post-transplantation cyclophosphamide vs. antithymocyte globulin after RIC regimen allo-HCT: first analysis of a prospective randomized multicenter trial in recipients of 10/10 matched donors [abstract O001]. Bone Marrow Transplant. 56 (Suppl. 1), 12 (2021).
Holtan, S. G. et al. Post-transplant cyclophosphamide, tacrolimus, and mycophenolate mofetil as the new standard for graft-versus-host disease (GVHD) prophylaxis in reduced intensity conditioning: results from phase III BMT CTN 1703 [abstract]. Blood 140 (Suppl. 2), LBA-4 (2022).
doi: 10.1182/blood-2022-171463
Luznik, L. et al. Randomized phase III BMT CTN trial of calcineurin inhibitor-free chronic graft-versus-host disease interventions in myeloablative hematopoietic cell transplantation for hematologic malignancies. J. Clin. Oncol. 40, 356–368 (2022).
pubmed: 34855460
doi: 10.1200/JCO.21.02293
Atilla, E., Atilla, P. A., Bozdag, S. C. & Demirer, T. A review of infectious complications after haploidentical hematopoietic stem cell transplantations. Infection 45, 403–411 (2017).
pubmed: 28417421
doi: 10.1007/s15010-017-1016-1
Duléry, R. et al. Early cardiac toxicity associated with post-transplant cyclophosphamide in allogeneic stem cell transplantation. JACC CardioOncol. 3, 250–259 (2021).
pubmed: 34396331
doi: 10.1016/j.jaccao.2021.02.011
El-Cheikh, J. et al. Impact of adding antithymocyte globulin to posttransplantation cyclophosphamide in haploidentical stem-cell transplantation. Clin. Lymphoma Myeloma Leuk. 20, 617–623 (2020).
pubmed: 32457025
doi: 10.1016/j.clml.2020.04.003
Pérez-Simón, J. A. et al. Nonmyeloablative transplantation with or without alemtuzumab: comparison between 2 prospective studies in patients with lymphoproliferative disorders. Blood 100, 3121–3127 (2002).
pubmed: 12384408
doi: 10.1182/blood-2002-03-0701
Kottaridis, P. D. et al. In vivo CAMPATH-1H prevents graft-versus-host disease following nonmyeloablative stem cell transplantation. Blood 96, 2419–2425 (2000).
pubmed: 11001893
doi: 10.1182/blood.V96.7.2419
Chakraverty, R. et al. Limiting transplantation-related mortality following unrelated donor stem cell transplantation by using a nonmyeloablative conditioning regimen. Blood 99, 1071–1078 (2002).
pubmed: 11807015
doi: 10.1182/blood.V99.3.1071
Malladi, R. K. et al. Alemtuzumab markedly reduces chronic GVHD without affecting overall survival in reduced-intensity conditioning sibling allo-SCT for adults with AML. Bone Marrow Transplant. 43, 709–715 (2009).
pubmed: 19029965
doi: 10.1038/bmt.2008.375
van Besien, K. et al. Fludarabine-melphalan conditioning for AML and MDS: alemtuzumab reduces acute and chronic GVHD without affecting long-term outcomes. Biol. Blood Marrow Transplant. 15, 610–617 (2009).
pubmed: 19361753
pmcid: 4348112
doi: 10.1016/j.bbmt.2009.01.021
Chen, Y.-B. et al. Vedolizumab for prophylaxis of lower gastrointestinal acute graft-versus-host disease after allogeneic hematopoietic stem-cell transplantation from unrelated donors: a phase 3, randomized, double-blind, placebo-controlled, multicenter study. Presented at the 49th EBMT Annual Meeting (2023).
Ponce, D. M. et al. Guidelines for the prevention and management of graft-versus-host disease after cord blood transplantation. Transplant. Cell Ther. 27, 540–544 (2021).
pubmed: 34210500
doi: 10.1016/j.jtct.2021.03.012
Bacigalupo, A. et al. Steroid treatment of acute graft-versus-host disease grade I: a randomized trial. Haematologica 102, 2125–2133 (2017).
pubmed: 28971905
pmcid: 5709112
doi: 10.3324/haematol.2017.171157
Mielcarek, M. et al. Initial therapy of acute graft-versus-host disease with low-dose prednisone does not compromise patient outcomes. Blood 113, 2888–2894 (2009).
pubmed: 19001082
pmcid: 2662636
doi: 10.1182/blood-2008-07-168401
Mielcarek, M. et al. Effectiveness and safety of lower dose prednisone for initial treatment of acute graft-versus-host disease: a randomized controlled trial. Haematologica 100, 842–848 (2015).
pubmed: 25682602
doi: 10.3324/haematol.2014.118471
Hockenbery, D. M. et al. A randomized, placebo-controlled trial of oral beclomethasone dipropionate as a prednisone-sparing therapy for gastrointestinal graft-versus-host disease. Blood 109, 4557–4563 (2007).
pubmed: 17244684
doi: 10.1182/blood-2006-05-021139
McDonald, G. B. et al. Oral beclomethasone dipropionate for treatment of intestinal graft-versus-host disease: a randomized, controlled trial. Gastroenterology 115, 28–35 (1998).
pubmed: 9649455
doi: 10.1016/S0016-5085(98)70361-0
Mohty, M. et al. Refractory acute graft-versus-host disease: a new working definition beyond corticosteroid refractoriness. Blood 136, 1903–1906 (2020).
pubmed: 32756949
doi: 10.1182/blood.2020007336
MacMillan, M. L., DeFor, T. E. & Weisdorf, D. J. The best endpoint for acute GVHD treatment trials. Blood 115, 5412–5417 (2010).
pubmed: 20388871
doi: 10.1182/blood-2009-12-258442
Alousi, A. M. et al. Etanercept, mycophenolate, denileukin, or pentostatin plus corticosteroids for acute graft-versus-host disease: a randomized phase 2 trial from the Blood and Marrow Transplant Clinical Trials Network. Blood 114, 511–517 (2009).
pubmed: 19443659
pmcid: 2713466
doi: 10.1182/blood-2009-03-212290
Bolanos-Meade, J. et al. Phase 3 clinical trial of steroids/mycophenolate mofetil vs steroids/placebo as therapy for acute GVHD: BMT CTN 0802. Blood 124, 3221–3227 (2014).
pubmed: 25170121
pmcid: 4239331
doi: 10.1182/blood-2014-06-577023
Couriel, D. R. et al. A phase III study of infliximab and corticosteroids for the initial treatment of acute graft-versus-host disease. Biol. Blood Marrow Transplant. 15, 1555–1562 (2009).
pubmed: 19896079
pmcid: 4114035
doi: 10.1016/j.bbmt.2009.08.003
Zeiser, R. et al. Efficacy and safety of itacitinib versus placebo in combination with corticosteroids for initial treatment of acute graft-versus-host disease (GRAVITAS-301): a randomised, multicentre, double-blind, phase 3 trial. Lancet Haematol. 9, e14–e25 (2022).
pubmed: 34971577
doi: 10.1016/S2352-3026(21)00367-7
Pidala, J. et al. Randomized multicenter trial of sirolimus vs prednisone as initial therapy for standard-risk acute GVHD: the BMT CTN 1501 trial. Blood 135, 97–107 (2020).
pubmed: 31738834
pmcid: 6952830
doi: 10.1182/blood.2019003125
Martin, P. J. et al. First- and second-line systemic treatment of acute graft-versus-host disease: recommendations of the American Society of Blood and Marrow Transplantation. Biol. Blood Marrow Transplant. 18, 1150–1163 (2012).
pubmed: 22510384
pmcid: 3404151
doi: 10.1016/j.bbmt.2012.04.005
Martin, P. J. How I treat steroid-refractory acute graft-versus-host disease. Blood 135, 1630–1638 (2020).
pubmed: 32202630
doi: 10.1182/blood.2019000960
Malard, F., Huang, X. J. & Sim, J. P. Y. Treatment and unmet needs in steroid-refractory acute graft-versus-host disease. Leukemia 34, 1229–1240 (2020).
pubmed: 32242050
pmcid: 7192843
doi: 10.1038/s41375-020-0804-2
Zeiser, R. et al. Ruxolitinib in corticosteroid-refractory graft-versus-host disease after allogeneic stem cell transplantation: a multicenter survey. Leukemia 29, 2062–2068 (2015).
pubmed: 26228813
pmcid: 4854652
doi: 10.1038/leu.2015.212
Jagasia, M. et al. Ruxolitinib for the treatment of steroid-refractory acute GVHD (REACH1): a multicenter, open-label, phase 2 trial. Blood https://doi.org/10.1182/blood.2020004823 (2020).
doi: 10.1182/blood.2020004823
pubmed: 32756949
pmcid: 7229262
Zeiser, R. et al. Ruxolitinib for glucocorticoid-refractory acute graft-versus-host disease. N. Engl. J. Med. 382, 1800–1810 (2020). To our knowledge, the first randomized study showing the superiority of a second-line treatment, ruxolitinib, for steroid-refractory acute GVHD.
pubmed: 32320566
doi: 10.1056/NEJMoa1917635
MacMillan, M. L. et al. A refined risk score for acute graft-versus-host disease that predicts response to initial therapy, survival, and transplant-related mortality. Biol. Blood Marrow Transplant. 21, 761–767 (2015).
pubmed: 25585275
pmcid: 4359643
doi: 10.1016/j.bbmt.2015.01.001
Marchetti, O. et al. ECIL recommendations for the use of biological markers for the diagnosis of invasive fungal diseases in leukemic patients and hematopoietic SCT recipients. Bone Marrow Transplant. 47, 846–854 (2012).
pubmed: 21927034
doi: 10.1038/bmt.2011.178
Yuan, Y. et al. High incidence of resistant breakthrough invasive fungal infections (IFD) in patients treated for acute gastrointestinal graft-versus-host disease (GI GVHD) following allogeneic haematopoietic cell transplantation. Bone Marrow Transplant. 57, 1712–1715 (2022).
pubmed: 35970876
doi: 10.1038/s41409-022-01773-9
Ullmann, A. J. et al. Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. N. Engl. J. Med. 356, 335–347 (2007).
pubmed: 17251530
doi: 10.1056/NEJMoa061098
Maertens, J. et al. ECIL guidelines for preventing Pneumocystis jirovecii pneumonia in patients with haematological malignancies and stem cell transplant recipients. J. Antimicrob. Chemother. 71, 2397–2404 (2016).
pubmed: 27550992
doi: 10.1093/jac/dkw157
Ljungman, P. et al. Guidelines for the management of cytomegalovirus infection in patients with haematological malignancies and after stem cell transplantation from the 2017 European Conference on Infections in Leukaemia (ECIL 7). Lancet Infect. Dis. 19, e260–e272 (2019).
pubmed: 31153807
doi: 10.1016/S1473-3099(19)30107-0
Wolfe, D. et al. Letermovir prophylaxis and cytomegalovirus reactivation in adult hematopoietic cell transplant recipients with and without acute graft versus host disease. Cancers https://doi.org/10.3390/cancers13215572 (2021).
doi: 10.3390/cancers13215572
pubmed: 34771734
pmcid: 8583331
Bansal, R. et al. Extended letermovir administration, beyond day 100, is effective for CMV prophylaxis in patients with graft versus host disease. Transplant. Infect. Dis. 23, e13487 (2021).
doi: 10.1111/tid.13487
Boeckh, M., Kim, H. W., Flowers, M. E., Meyers, J. D. & Bowden, R. A. Long-term acyclovir for prevention of varicella zoster virus disease after allogeneic hematopoietic cell transplantation – a randomized double-blind placebo-controlled study. Blood 107, 1800–1805 (2006).
pubmed: 16282339
pmcid: 1895699
doi: 10.1182/blood-2005-09-3624
Klein, A., Miller, K. B., Sprague, K., DesJardin, J. A. & Snydman, D. R. A randomized, double-blind, placebo-controlled trial of valacyclovir prophylaxis to prevent zoster recurrence from months 4 to 24 after BMT. Bone Marrow Transplant. 46, 294–299 (2011).
pubmed: 20421867
doi: 10.1038/bmt.2010.99
Stocker, N. et al. Pre-emptive rituximab treatment for Epstein–Barr virus reactivation after allogeneic hematopoietic stem cell transplantation is a worthwhile strategy in high-risk recipients: a comparative study for immune recovery and clinical outcomes. Bone Marrow Transplant. 55, 586–594 (2020).
pubmed: 31562397
doi: 10.1038/s41409-019-0699-6
Engelhard, D., Mohty, B., de la Camara, R., Cordonnier, C. & Ljungman, P. European guidelines for prevention and management of influenza in hematopoietic stem cell transplantation and leukemia patients: summary of ECIL-4 (2011), on behalf of ECIL, a joint venture of EBMT, EORTC, ICHS, and ELN. Transplant. Infect. Dis. 15, 219–232 (2013).
doi: 10.1111/tid.12054
Piñana, J. L. et al. Clinical effectiveness of influenza vaccination after allogeneic hematopoietic stem cell transplantation: a cross-sectional, prospective, observational study. Clin. Infect. Dis. 68, 1894–1903 (2019).
pubmed: 30239624
doi: 10.1093/cid/ciy792
Cesaro, S. et al. Recommendations for the management of COVID-19 in patients with haematological malignancies or haematopoietic cell transplantation, from the 2021 European Conference on Infections in Leukaemia (ECIL 9). Leukemia 36, 1467–1480 (2022).
pubmed: 35488021
pmcid: 9053562
doi: 10.1038/s41375-022-01578-1
Machado, C. M. et al. Use of oseltamivir to control influenza complications after bone marrow transplantation. Bone Marrow Transplant. 34, 111–114 (2004).
pubmed: 15094755
doi: 10.1038/sj.bmt.1704534
Hammond, J. et al. Oral nirmatrelvir for high-risk, nonhospitalized adults with Covid-19. N. Engl. J. Med. 386, 1397–1408 (2022).
pubmed: 35172054
doi: 10.1056/NEJMoa2118542
Lemaitre, F. et al. Therapeutic drug monitoring and dosage adjustments of immunosuppressive drugs when combined with nirmatrelvir/ritonavir in patients with COVID-19. Ther. Drug Monit. 45, 191–199 (2023).
pubmed: 35944126
doi: 10.1097/FTD.0000000000001014
Raanani, P. et al. Immunoglobulin prophylaxis in hematopoietic stem cell transplantation: systematic review and meta-analysis. J. Clin. Oncol. 27, 770–781 (2009).
pubmed: 19114702
doi: 10.1200/JCO.2008.16.8450
Ljungman, P. et al. Vaccination of stem cell transplant recipients: recommendations of the Infectious Diseases Working Party of the EBMT. Bone Marrow Transplant. 35, 737–746 (2005).
pubmed: 15750612
doi: 10.1038/sj.bmt.1704870
Cordonnier, C. et al. Vaccination of haemopoietic stem cell transplant recipients: guidelines of the 2017 European Conference on Infections in Leukaemia (ECIL 7). Lancet Infect. Dis. 19, e200–e212 (2019).
pubmed: 30744963
doi: 10.1016/S1473-3099(18)30600-5
Averbuch, D. et al. European guidelines for empirical antibacterial therapy for febrile neutropenic patients in the era of growing resistance: summary of the 2011 4th European Conference on Infections in Leukemia. Haematologica 98, 1826–1835 (2013).
pubmed: 24323983
pmcid: 3856957
doi: 10.3324/haematol.2013.091025
Seibel, M. J., Cooper, M. S. & Zhou, H. Glucocorticoid-induced osteoporosis: mechanisms, management, and future perspectives. Lancet Diabetes Endocrinol. 1, 59–70 (2013).
pubmed: 24622268
doi: 10.1016/S2213-8587(13)70045-7
Li, J.-X. & Cummins, C. L. Fresh insights into glucocorticoid-induced diabetes mellitus and new therapeutic directions. Nat. Rev. Endocrinol. 18, 540–557 (2022).
pubmed: 35585199
pmcid: 9116713
doi: 10.1038/s41574-022-00683-6
Aaronson, N. K. et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J. Natl Cancer Inst. 85, 365–376 (1993).
pubmed: 8433390
doi: 10.1093/jnci/85.5.365
McQuellon, R. P. et al. Quality of life measurement in bone marrow transplantation: development of the Functional Assessment of Cancer Therapy–Bone Marrow Transplant (FACT-BMT) scale. Bone Marrow Transplant. 19, 357–368 (1997).
pubmed: 9051246
doi: 10.1038/sj.bmt.1700672
Lent, L., Hahn, E., Eremenco, S., Webster, K. & Cella, D. Using cross-cultural input to adapt the Functional Assessment of Chronic Illness Therapy (FACIT) scales. Acta Oncol. 38, 695–702 (1999).
pubmed: 10522759
doi: 10.1080/028418699432842
Ware, J. Jr., Kosinski, M. & Keller, S. D. A 12-Item Short-Form Health Survey: construction of scales and preliminary tests of reliability and validity. Med. Care 34, 220–233 (1996).
pubmed: 8628042
doi: 10.1097/00005650-199603000-00003
Lee, S. J. et al. Quality of life associated with acute and chronic graft-versus-host disease. Bone Marrow Transplant. 38, 305–310 (2006).
pubmed: 16819438
doi: 10.1038/sj.bmt.1705434
Rashid, N. et al. Late effects of severe acute graft-versus-host disease on quality of life, medical comorbidities, and survival. Transplant. Cell Ther. https://doi.org/10.1016/j.jtct.2022.08.027 (2022).
doi: 10.1016/j.jtct.2022.08.027
pubmed: 36057421
Grube, M. et al. Risk factors and outcome of chronic graft-versus-host disease after allogeneic stem cell transplantation – results from a single-center observational study. Biol. Blood Marrow Transplant. 22, 1781–1791 (2016).
pubmed: 27343720
doi: 10.1016/j.bbmt.2016.06.020
Boyiadzis, M. et al. Impact of chronic graft-versus-host disease on late relapse and survival on 7,489 patients after myeloablative allogeneic hematopoietic cell transplantation for leukemia. Clin. Cancer Res. 21, 2020–2028 (2015).
pubmed: 25348512
doi: 10.1158/1078-0432.CCR-14-0586
Pidala, J., Anasetti, C. & Jim, H. Quality of life after allogeneic hematopoietic cell transplantation. Blood 114, 7–19 (2009).
pubmed: 19336756
pmcid: 2710956
doi: 10.1182/blood-2008-10-182592
Brice, L. et al. Predictors of quality of life in allogeneic hematopoietic stem cell transplantation survivors. J. Psychosoc. Oncol. 39, 534–552 (2021).
pubmed: 33468039
doi: 10.1080/07347332.2020.1870644
Norkin, M., Hsu, J. W. & Wingard, J. R. Quality of life, social challenges, and psychosocial support for long-term survivors after allogeneic hematopoietic stem-cell transplantation. Semin. Hematol. 49, 104–109 (2012).
pubmed: 22221790
doi: 10.1053/j.seminhematol.2011.10.004
Loberiza, F. R. Jr. et al. Association of depressive syndrome and early deaths among patients after stem-cell transplantation for malignant diseases. J. Clin. Oncol. 20, 2118–2126 (2002).
pubmed: 11956273
doi: 10.1200/JCO.2002.08.757
Clark, C. A., Savani, M., Mohty, M. & Savani, B. N. What do we need to know about allogeneic hematopoietic stem cell transplant survivors. Bone Marrow Transplant. 51, 1025–1031 (2016).
pubmed: 27064688
doi: 10.1038/bmt.2016.95
Arnhold, V. et al. Corticosteroid treatment impairs epithelial regeneration, limiting intestinal recovery in experimental graft vs host disease [abstract]. Blood 138 (Suppl. 1), 88 (2021).
doi: 10.1182/blood-2021-154500
Hanash, A. M. et al. Interleukin-22 protects intestinal stem cells from immune-mediated tissue damage and regulates sensitivity to graft versus host disease. Immunity 37, 339–350 (2012).
pubmed: 22921121
pmcid: 3477611
doi: 10.1016/j.immuni.2012.05.028
Lindemans, C. A. et al. Interleukin-22 promotes intestinal-stem-cell-mediated epithelial regeneration. Nature 528, 560–564 (2015).
pubmed: 26649819
pmcid: 4720437
doi: 10.1038/nature16460
Hummel, S. et al. Telomere shortening in enterocytes of patients with uncontrolled acute intestinal graft-versus-host disease. Blood 126, 2518–2521 (2015).
pubmed: 26486788
doi: 10.1182/blood-2015-03-633289
Malard, F., Gaugler, B. & Mohty, M. Faecal microbiota transplantation in patients with haematological malignancies undergoing cellular therapies: from translational research to routine clinical practice. Lancet Haematol. 9, e776–e785 (2022).
pubmed: 36174640
doi: 10.1016/S2352-3026(22)00223-X
Shouval, R., Geva, M., Nagler, A. & Youngster, I. Fecal microbiota transplantation for treatment of acute graft-versus-host disease. Clin. Hematol. Int. 1, 28–35 (2019).
pubmed: 34595408
pmcid: 8432378
doi: 10.2991/chi.d.190316.002
Qiao, X. et al. Safety and efficacy of fecal microbiota transplantation in the treatment of graft-versus-host disease. Bone Marrow Transplant. https://doi.org/10.1038/s41409-022-01824-1 (2022).
doi: 10.1038/s41409-022-01824-1
pubmed: 36289371
Sirohi, B. & Mathew, A. Access to and affordability of cancer medicines: time to focus on the last mile. Lancet Oncol. 22, 1342–1343 (2021).
pubmed: 34560007
doi: 10.1016/S1470-2045(21)00518-0
Bleakley, M. & Riddell, S. R. Molecules and mechanisms of the graft-versus-leukaemia effect. Nat. Rev. Cancer 4, 371–380 (2004).
pubmed: 15122208
doi: 10.1038/nrc1365
Copelan, E. A. Hematopoietic stem-cell transplantation. N. Engl. J. Med. 354, 1813–1826 (2006).
pubmed: 16641398
doi: 10.1056/NEJMra052638
Bacigalupo, A. et al. Defining the intensity of conditioning regimens: working definitions. Biol. Blood Marrow Transplant. 15, 1628–1633 (2009).
pubmed: 19896087
pmcid: 2861656
doi: 10.1016/j.bbmt.2009.07.004
Gragert, L. et al. HLA match likelihoods for hematopoietic stem-cell grafts in the US registry. N. Engl. J. Med. 371, 339–348 (2014).
pubmed: 25054717
pmcid: 5965695
doi: 10.1056/NEJMsa1311707
Kanakry, C. G., Fuchs, E. J. & Luznik, L. Modern approaches to HLA-haploidentical blood or marrow transplantation. Nat. Rev. Clin. Oncol. 13, 10–24 (2016).
pubmed: 26305035
doi: 10.1038/nrclinonc.2015.128